CAP-1002 is under clinical development by Capricor Therapeutics and currently in Phase I for Pulmonary Arterial Hypertension. According to GlobalData, Phase I drugs for Pulmonary Arterial Hypertension have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CAP-1002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CAP-1002 overview

CAP-1002 is under development for the treatment of pulmonary arterial hypertension (PAH) and Duchenne muscular dystrophy (DMD). The therapeutic candidate is an allogeneic cardiosphere-derived stem cell (CDC) administered through intravenous and intracoronary routes. It is a new molecular entity (NME) being developed based on CDC technology.
The therapeutic candidate was under development for the treatment of dilated cardiomyopathy, myocardial infarction, cardiomyopathy and ischemic left ventricular dysfunction, coronavirus disease 2019 (COVID-19), advanced heart failure and ischemic heart disease.

Capricor Therapeutics overview

Capricor Therapeutics (Capricor) is a biotechnology company that focuses on the development and commercialization of exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other rare disorders. The company pipeline product includes CAP-1002 is an allogeneic cardiosphere-derived cell product for the treatment of adult cardiology indications. Capricor technology comprises CAP-2003 for clinical development. The company is develops its exosome technologies as a next generation platform for a variety of diseases. It offers research programs on cell therapy, natriuretic peptides and exosome platforms. The company also conducts clinical trials for the development of novel therapeutics to prevent and treat cardiac and other serious medical conditions. Capricor is headquartered inBeverly Hills, California, the US.

For a complete picture of CAP-1002’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.